Program Description
Hyperglycemia is a common and clinically significant adverse effect associated with treatment with PI3K and AKT inhibitors in hormone receptor-positive (HR+) breast cancer. Hyperglycemia occurs because the PI3K/AKT pathway, which is targeted by these therapies to inhibit cancer cell growth, also plays a crucial role in normal glucose metabolism. This webinar will provide oncology pharmacists with a comprehensive overview of the PI3K/AKT/PTEN/mTOR pathway and its role in HR+ breast cancer, as well as the mechanism of action for the PI3K and AKT inhibitors. The pathophysiology of hyperglycemia induced by these agents will be the focus of the discussion, equipping oncology pharmacists with the knowledge to identify patients at risk and prepare for this common adverse effect. If not promptly identified and managed, hyperglycemia can lead to serious consequences, including dose interruptions or reductions that may compromise the effectiveness of the anti-cancer treatment for patients. The program will also review the incidence and severity of hyperglycemia as observed in pivotal clinical trials as well as in real-world settings.
Target audience: Oncology pharmacists, health system pharmacists, ambulatory care pharmacists
Type of activity: Application
Release date: October 14, 2025
Expiration date: December 15, 2025
Time to complete activity: 1.0 hour
Learner level: Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the mechanism of action, mutation targets, and clinical indications for FDA-approved PI3K and AKT inhibitors
- Explain the pathophysiologic mechanisms by which PI3K and AKT inhibitors cause hyperglycemia and how these differ from other drug-induced hyperglycemia mechanisms
- Analyze real-world and clinical trial data on the incidence of hyperglycemia in patients receiving PI3K and AKT inhibitors
Taylor Monson, PharmD, BCPS, BCOP
Clinical Oncology Pharmacist, Breast Oncology
Clinical Oncology Team Lead, Solid Tumors
The University of Kansas Health System
Kansas City, KS
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-293-L05-P. The activity is available for CE credit through December 14, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Taylor Monson, PharmD, BCPS, BCOP, has the following financial relationships with ineligible companies to disclose:
Advisory Boards: AstraZeneca, Eli Lilly
Pharmacy Times Continuing Education™ Planning Staff - Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms